Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.34 |
| ▸ | THRA | P10827 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.30 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12734543 | 0.99 | HDAC8 (0.36) | HDAC8S1PR1S1PR3AHRPTPN11 | |
| SCHEMBL12734538 | 0.99 | HDAC8 (0.36) | HDAC8S1PR1S1PR3AHRPTPN11 | |
| SCHEMBL12734540 | 0.99 | HDAC8 (0.36) | HDAC8S1PR1S1PR3AHRPTPN11 | |
| SCHEMBL12734528 | 0.98 | AHR (0.35) | HDAC8S1PR1S1PR3AHRPTPN11 | |
| SCHEMBL12739477 | 0.93 | HDAC8 (0.36) | HDAC8S1PR1S1PR3AHRPTPN11 | |
| SCHEMBL12739483 | 0.92 | HDAC8 (0.36) | HDAC8AHRPTPN11THRATHRB | |
| SCHEMBL12739481 | 0.92 | HDAC8 (0.36) | HDAC8AHRPTPN11THRATHRB | |
| SCHEMBL12739480 | 0.92 | HDAC8 (0.36) | HDAC8AHRPTPN11THRATHRB | |
| SCHEMBL12739475 | 0.91 | AHR (0.35) | HDAC8S1PR1S1PR3AHRPTPN11 | |
| SCHEMBL12734525 | 0.91 | HMOX1 (0.35) | AHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | HDAC8 4142/4885S1PR1 1190/4885S1PR3 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.